Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabotegravir

FDA-approved product (suspension, extended release, intramuscular), marketed as Apretude, Vocabria.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cabotegravir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Integrase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AJ04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabotegravir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabotegravir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

    NCT04518228 · start 2021-09-01

    Registered record
    Registry ID
    NCT04518228
    Conditions
    HIV; Tuberculosis
    Interventions
    Bictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG); Atazanavir/ritonavir (ATV/r); Darunavir/ritonavir (DRV/r); Lopinavir/ritonavir (LPV/r); Cobicistat; Ritonavir; First-Line TB Treatment; Second-Line TB Treatment; Doravirine (DOR)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2021-09-01
    Completion
    2025-07-10
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Tuberculosis
    InterventionBictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG) +8 more
    PhaseNot recorded
    Registry statusTerminated

  • HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

    NCT04979728 · start 2021-05-27

    Registered record
    Registry ID
    NCT04979728
    Conditions
    HIV Treatment; HIV Prevention
    Interventions
    At Home Self-Collections
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-05-27
    Completion
    2027-06-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Treatment; HIV Prevention
    InterventionAt Home Self-Collections
    PhaseNot recorded
    Registry statusRecruiting

  • A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

    NCT04542070 · start 2020-11-09

    Registered record
    Registry ID
    NCT04542070
    Conditions
    HIV Infections
    Interventions
    Cabotegravir Tablets; Cabotegravir Injectable Suspension (CAB LA); Rilpivirine Tablets; Rilpivirine Injectable Suspension (RPV LA); BIKTARVY Tablets (BIK)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-11-09
    Completion
    2023-04-17
    Enrolment
    687

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir Tablets; Cabotegravir Injectable Suspension (CAB LA); Rilpivirine Tablets; Rilpivirine Injectable Suspension (RPV LA) +1 more
    PhasePhase 3
    Registry statusCompleted

  • Long-acting Biomedical HIV Prevention in Transgender Women

    NCT03856580 · start 2020-10-23

    Registered record
    Registry ID
    NCT03856580
    Conditions
    HIV Prevention; Transgender Women
    Interventions
    Alternative long-acting PrEP injection strategies; mHealth adherence app
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2020-10-23
    Completion
    2023-04-30
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Prevention; Transgender Women
    InterventionAlternative long-acting PrEP injection strategies; mHealth adherence app
    PhaseNot applicable
    Registry statusTerminated

  • A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

    NCT04399551 · start 2020-09-28

    Registered record
    Registry ID
    NCT04399551
    Conditions
    HIV Infections
    Interventions
    CAB OLI; CAB LA; RPV OLI; RPV LA; Continuous Quality Improvement (CQI) calls
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-28
    Completion
    2023-03-13
    Enrolment
    437

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCAB OLI; CAB LA; RPV OLI; RPV LA +1 more
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

    NCT04484337 · start 2020-07-31

    Registered record
    Registry ID
    NCT04484337
    Conditions
    HIV Infections
    Interventions
    Cabotegravir sodium (Oral Lead In); Cabotegravir 400 mg/mL; Cabotegravir 200 mg/mL; Topical Non-steroidal anti-inflammatory drug (NSAID); Topical steroid; Topical NSAID placebo; Recombinant human hyaluronidase PH20 (rHuPH20); Topical steroid placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-07-31
    Completion
    2023-05-05
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir sodium (Oral Lead In); Cabotegravir 400 mg/mL; Cabotegravir 200 mg/mL; Topical Non-steroidal anti-inflammatory drug (NSAID) +4 more
    PhasePhase 1
    Registry statusCompleted

  • Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

    NCT04692077 · start 2020-02-19

    Registered record
    Registry ID
    NCT04692077
    Conditions
    HIV Infections
    Interventions
    Cabotegravir (CAB) tablet; CAB LA; Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-02-19
    Completion
    2023-07-07
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir (CAB) tablet; CAB LA; Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
    PhasePhase 2
    Registry statusCompleted

  • Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

    NCT03739996 · start 2019-12-31

    Registered record
    Registry ID
    NCT03739996
    Conditions
    HIV Infections
    Interventions
    Oral Cabotegravir (CAB); Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Long-Acting Injectable Cabotegravir (CAB LA); VRC07-523LS; Standard of Care (SOC) ART
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-12-31
    Completion
    2024-04-29
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionOral Cabotegravir (CAB); Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Long-Acting Injectable Cabotegravir (CAB LA); VRC07-523LS +1 more
    PhasePhase 2
    Registry statusCompleted

  • Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

    NCT03639311 · start 2018-09-24

    Registered record
    Registry ID
    NCT03639311
    Conditions
    HIV Infections
    Interventions
    CAB LA; RPV LA; RPV; DTG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-09-24
    Completion
    2023-01-30
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCAB LA; RPV LA; RPV; DTG
    PhasePhase 2
    Registry statusCompleted

  • A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men

    NCT03422172 · start 2018-04-10

    Registered record
    Registry ID
    NCT03422172
    Conditions
    HIV Infections
    Interventions
    Oral CAB; CAB LA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-04-10
    Completion
    2020-04-20
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionOral CAB; CAB LA
    PhasePhase 1
    Registry statusCompleted

  • Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

    NCT03164564 · start 2017-11-07

    Registered record
    Registry ID
    NCT03164564
    Conditions
    HIV Infections
    Interventions
    Oral CAB; Oral TDF/FTC; Placebo for oral CAB; Placebo for oral TDF/FTC; CAB LA; Placebo for CAB LA
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-11-07
    Completion
    2026-10-17
    Enrolment
    3,224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionOral CAB; Oral TDF/FTC; Placebo for oral CAB; Placebo for oral TDF/FTC +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

    NCT03299049 · start 2017-10-27

    Registered record
    Registry ID
    NCT03299049
    Conditions
    HIV Infections
    Interventions
    Cabotegravir Tablets; Rilpivirine Tablets; Cabotegravir Injectable Suspension; Rilpivirine Injectable Suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-10-27
    Completion
    2029-12-31
    Enrolment
    1,049

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir Tablets; Rilpivirine Tablets; Cabotegravir Injectable Suspension; Rilpivirine Injectable Suspension
    PhasePhase 3
    Registry statusActive not recruiting

  • Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

    NCT02720094 · start 2016-12-19

    Registered record
    Registry ID
    NCT02720094
    Conditions
    HIV Infections
    Interventions
    Cabotegravir Oral Tablet; TDF/FTC tablets; Placebo for TDF/FTC tablets; Placebo for cabotegravir oral tablet; CAB LA; Placebo for CAB LA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-12-19
    Completion
    2025-03-31
    Enrolment
    4,570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir Oral Tablet; TDF/FTC tablets; Placebo for TDF/FTC tablets; Placebo for cabotegravir oral tablet +2 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

    NCT02938520 · start 2016-10-27

    Registered record
    Registry ID
    NCT02938520
    Conditions
    HIV Infections
    Interventions
    Cabotegravir (CAB) tablet; Rilpivirine (RPV) tablet; Cabotegravir - Injectable Suspension (CAB LA); Rilpivirine - Injectable Suspension (RPV LA); ABC/DTG/3TC STR - Tablet; DTG Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2016-10-27
    Completion
    2029-12-31
    Enrolment
    631

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir (CAB) tablet; Rilpivirine (RPV) tablet; Cabotegravir - Injectable Suspension (CAB LA); Rilpivirine - Injectable Suspension (RPV LA) +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

    NCT02799264 · start 2016-06

    Registered record
    Registry ID
    NCT02799264
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    Cabotegravir 30 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06
    Completion
    2016-08
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionCabotegravir 30 mg
    PhasePhase 1
    Registry statusCompleted